Histopathology of pembrolizumab-induced hepatitis: a case report

Pathology

Volumn 49, Issue 7, 2017, Pages 789-792

  Aivazian, Karina ^a   Long, Georgina V ^b,c,d   Sinclair, Elizabeth C ^e   Kench, James G ^a,c   McKenzie, Catriona A ^a,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; METHYLPREDNISOLONE; PEMBROLIZUMAB; PHENYTOIN; PREDNISONE; MONOCLONAL ANTIBODY;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTICONVULSANT THERAPY; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LIVER BIOPSY; LIVER TISSUE; MALE; METASTATIC MELANOMA; PALLIATIVE THERAPY; PRIORITY JOURNAL; SCLERODERMA; SEIZURE; COMPLICATION; DIFFUSE SCLERODERMA; GENETICS; MELANOMA; PATHOLOGY; TOXIC HEPATITIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMICAL AND DRUG INDUCED LIVER INJURY; HEPATITIS; HUMANS; MALE; MELANOMA; SCLERODERMA, DIFFUSE;

EID: 85032033116     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1016/j.pathol.2017.07.010     Document Type: Letter

References (12)

1. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
2. Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab vs ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
3. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
4. Naidoo, J., Page, D.B., Li, B.T., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26 (2015), 2375–2391.
5. Castiella, A., Zapata, E., Lucena, M.I., et al. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol 6 (2014), 160–168.
6. Eigentler, T.K., Hassel, J.C., Berking, C., et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45 (2016), 7–18.
7. Kleiner, D.E., Berman, D., Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57 (2012), 2233–2240.
8. Johncilla, M., Misdraji, J., Pratt, D.S., et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39 (2015), 1075–1084.
9. Kim, K.W., Ramaiya, N.H., Krajewski, K.M., et al. Ipilimumab associated hepatitis: imaging and clinicopathological findings. Invest New Drugs 31 (2013), 1071–1077.
10. Cheng, R., Cooper, A., Kench, J., et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30 (2015), 657–666.
11. Everett, J., Srivastava, A., Misdraji, J., Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol 41 (2017), 134–137.
12. Suzuki, A., Brunt, E.M., Kleiner, D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 54 (2011), 931–939.